Open Access

Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma

  • Authors:
    • Jiehao Huang
    • Hongwu Chen
    • Quantang Wei
    • Ziheng Zhang
    • Zhiwei Zhong
    • Yimin Xu
  • View Affiliations

  • Published online on: January 23, 2017     https://doi.org/10.3892/ol.2017.5631
  • Pages: 1688-1694
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The liver kinase B1 (LKB1)/5'‑adenosine monophosphate‑activated protein kinase pathway has been reported to facilitate glioma cell growth by improving growth conditions. To investigate the clinical significance of LKB1 in human gliomas western blot analysis and quantitative polymerase chain reaction experiments were performed. The present study demonstrated that LKB1 expression was markedly decreased at the messenger RNA and protein levels in 30 freshly prepared glioma tissues, compared with non‑neoplastic brain tissues (P<0.001). Subsequently, immunohistochemical analysis demonstrated that LKB1 immunostaining in 180 glioma tissues was significantly decreased compared with that in the corresponding non‑neoplastic brain tissues (P<0.001). Notably, this downregulation frequently occurred in high‑grade gliomas, and statistical analysis revealed that low LKB1 expression was significantly associated with large tumor size (P=0.02), advanced World Health Organization grade (P=0.006) and low Karnofsky performance scale (P=0.01). The prognostic value of LKB1 expression in patients with glioma was additionally evaluated using Kaplan‑Meier survival curves and Cox proportional hazards regression models. As a result, the overall survival time of patients with glioma with low LKB1 expression was shorter compared with that of patients with high LKB1 expression (P<0.001), and low LKB1 expression also indicated decreased survival time in patients with high‑grade glioma (P<0.001). Collectively, the present data indicated that the downregulation of LKB1 was closely associated with the malignant degree of human gliomas, exhibiting lower expression at a higher grade. Notably, LKB1 may serve as a potential prognostic biomarker for patients with glioma following surgery.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang J, Chen H, Wei Q, Zhang Z, Zhong Z and Xu Y: Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma. Oncol Lett 13: 1688-1694, 2017
APA
Huang, J., Chen, H., Wei, Q., Zhang, Z., Zhong, Z., & Xu, Y. (2017). Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma. Oncology Letters, 13, 1688-1694. https://doi.org/10.3892/ol.2017.5631
MLA
Huang, J., Chen, H., Wei, Q., Zhang, Z., Zhong, Z., Xu, Y."Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma". Oncology Letters 13.3 (2017): 1688-1694.
Chicago
Huang, J., Chen, H., Wei, Q., Zhang, Z., Zhong, Z., Xu, Y."Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma". Oncology Letters 13, no. 3 (2017): 1688-1694. https://doi.org/10.3892/ol.2017.5631